Telix Pharmaceuticals Shares Climb After FDA Clears Pixclara

A 7.9% surge in premarket trading greeted Telix Pharmaceuticals on Monday following the Food and Drug Administration's approval of Pixclara, a diagnostic agent designed to map brain cancer. The company’s American depositary receipts hit $12.18, extending a sharp rally that has seen the stock climb 51% since the start of the year.

Today, 11:23· Money Talk· 172 reads

Pixclara functions as a radioactive diagnostic tool for positron emission tomography, allowing clinicians to distinguish between recurrent gliomas and post-treatment tissue changes. Gliomas remain the most prevalent form of central nervous system malignancy, representing 80% of all malignant brain tumors. By securing this regulatory clearance, Telix becomes the first provider to offer an FDA-approved PET imaging agent specifically for glioma management.

Chief Executive Kevin Richardson highlighted the clinical impact of the decision, noting that the drug offers physicians increased diagnostic precision and clarity when mapping patient treatment plans. The approval marks a significant expansion of the company’s oncology portfolio within the U.S. market.

Telix Pharmaceuticals Shares Climb After FDA Clears Pixclara

Comments (0)